Clinical outcomes with BG-12 treatment in CONFIRM (Comparator and an oral fumarate in relapsing- remitting multiple sclerosis) a multicentre, randomised, placebo-controlled, phase 3 study.

The requested reference [13cb904dc562a5dfb008e961f85b96bfe9ae805a] no longer exists in our database. It has been replaced by the current reference: [c67c4d86e023960b324671a7c74a9a936bb57ef4]

Authors
Category Primary study
JournalJournal of Neurology
Year 2012
This article has no abstract
Epistemonikos ID: fefd5540290809da597701823f77c6a036380b2c
First added on: Jul 16, 2016